Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
BSX US​

Boston Scientific Corp(BSX US)

$45.69-0.320.70%Ext:$45.33-0.360.79%(Market Closed · 00:00:04 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Boston Scientific Corp — Company Profile

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Michael F. Mahoney
Headquarters
Marlborough, MA, US
IPO Date
May 19, 1992
Employees
59,000
Website
www.bostonscientific.com

Key Metrics

Price
$42.60
Market Cap
$63.32B
Revenue (TTM)
$5.20B
Net Income (TTM)
$1.34B
EPS (TTM)
0.90
P/E (TTM)
17.82
P/B (TTM)
2.45
Dividend Yield
0.00%
ROE (TTM)
5.17%
ROA (TTM)
3.01%
Operating Margin
20.60%
Beta
0.20

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Website
www.bostonscientific.com
Location
Marlborough, MA, US
Phone508 683 4000
Employees59,000
CEOMichael F. Mahoney
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateMay 19, 1992

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(4.8K)

Expand
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers7 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers23 Sep
  • 8-K<ITEMS>1.058 Sep
  • 4O'Connor Padraig Andrew3 Sep
  • 4Morano Susan E26 Aug
  • 8-KOther Events26 Aug
  • 4Woodworth Emily12 Aug
  • 4Monson Jonathan11 Aug
  • 4Habiger David C7 Aug
  • SC 13G/ABOSTON SCIENTIFIC CORP6 Aug
  • 4Habiger David C5 Aug
  • 4Mahoney Michael F5 Aug
  • 4LUDWIG EDWARD J3 Aug
  • 4Fitzgerald Joseph Michael3 Aug
  • 10-QQ2ended 30 Jun 20263 Aug
  • 8-KResults of Operations and Financial Condition29 Jul
  • 8-KCost Associated with Exit or Disposal Activities27 Jul
  • 4Monson Jonathan2 Jul
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)24 Jun
  • 4Mahoney Michael F1 Jun

News

  • Insights Into Boston Scientific (BSX) Q3: Wall Street Projections for Key Metrics23 Oct
  • Boston Scientific Corporation $BSX Stock Bought by Integrated Advisors Network LLC23 Oct
  • Boston Scientific: A Q3 Earnings Miss Likely Amid Product Recall, Cybersecurity Incident22 Oct
  • BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT:  Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties -- BSX22 Oct
  • BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT:  Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties – BSX22 Oct
  • Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors21 Oct
  • Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth21 Oct
  • BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance?21 Oct
  • Boston Scientific Corporation $BSX Stake Raised by Louisbourg Investments Inc.21 Oct
  • Belo Sun Mining (TSE:BSX) Insider Ian Pritchard Sells 66,666 Shares of Stock20 Oct
  • Banque Pictet & Cie SA Sells 694,882 Shares of Boston Scientific Corporation $BSX17 Oct
  • First Citizens Bank & Trust Co. Buys New Shares in Boston Scientific Corporation $BSX16 Oct
  • Boston Scientific (BSX) Rises Higher Than Market: Key Facts15 Oct
  • Perpetual Ltd Purchases 24,355 Shares of Boston Scientific Corporation $BSX14 Oct
  • Boston Scientific (NYSE:BSX) and Sysmex (OTCMKTS:SSMXY) Critical Survey12 Oct
  • Why Boston Scientific (BSX) Outpaced the Stock Market Today9 Oct
  • Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors8 Oct
  • Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know8 Oct
  • Boston Scientific (NYSE:BSX) Reaches New 1-Year Low – Time to Sell?8 Oct
  • Boston Scientific (NYSE: BSX) names Fitzgerald COO, splits into 3 segments7 Oct

Mentions in Filings

  • … s led OrbiMed’s investments in several healthcare companies that achieved significant outcomes, including Crinetics Pharmaceuticals, Inc. (acquired by Vertex Pharmaceuticals in 2026), Bolt Medical, Inc. (acquired by <strong>Boston Scientific</strong> in 2025), Aliada Therapeutics, Inc. (acquired by AbbVie in 2024), RayzeBio, Inc. (acquired by Bristol-Myers Squibb in 2024), VectivBio Holding AG (acquired by Ironwood Pharmaceuticals in 2023), Therachon Holding AG ( …
    WINDWARD BIO GROUP AGBoston Scientific Corp·F-1 - Registration statement (foreign issuer)·Q4 26·23 Oct
  • … ommercially available advanced therapies used in patients with motor fluctuations despite optimization of L‑dopa, including DBS devices such as Infinity and Liberta RC (both marketed by Abbott), Vercise (marketed by <strong>Boston Scientific</strong>), and Percept (marketed by Medtronic), as well as Focused Ultrasound (FUS) technologies such as Exablate Neuro (marketed by Insightec). We anticipate that there will continue to be improvements in DBS and FUS technol …
    Aspen Neuroscience, Inc.Boston Scientific Corp·S-1/A - Registration statement (general form, amendment)·Q4 26·22 Oct
  • … s led OrbiMed's investments in several healthcare companies that achieved significant outcomes, including Crinetics Pharmaceuticals, Inc. (acquired by Vertex Pharmaceuticals in 2026), Bolt Medical, Inc. (acquired by <strong>Boston Scientific</strong> in 2025), Aliada Therapeutics, Inc. (acquired by AbbVie in 2024), RayzeBio, Inc. (acquired by Bristol-Myers Squibb in 2024), VectivBio Holding AG (acquired by Ironwood Pharmaceuticals in 2023), Therachon Holding AG ( …
    STANDARD BIOTOOLS INC.Boston Scientific Corp·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·21 Oct
  • … s led OrbiMed's investments in several healthcare companies that achieved significant outcomes, including Crinetics Pharmaceuticals, Inc. (acquired by Vertex Pharmaceuticals in 2026), Bolt Medical, Inc. (acquired by <strong>Boston Scientific</strong> in 2025), Aliada Therapeutics, Inc. (acquired by AbbVie in 2024), RayzeBio, Inc. (acquired by Bristol-Myers Squibb in 2024), VectivBio Holding AG (acquired by Ironwood Pharmaceuticals in 2023), Therachon Holding AG ( …
    STANDARD BIOTOOLS INC.Boston Scientific Corp·S-4/A - Registration statement (business combination, amendment)·Q4 26·21 Oct
  • Yoshiaki Fujimori has served as a member of our Board since January 2025. Mr. Fujimori has served as an outside director for Takeda Pharmaceutical Company Limited (NYSE: TAK) since June 2016 and <strong>Boston Scientific Corporation</strong> (NYSE: BSX) since July 2016, and as an outside director and Chairman for Oracle Japan Corporation since August 2018. He has been a partner of Corporate Support Research Institute Ltd., a private equity firm, since July 2023. …
    Blaize Holdings, Inc.Boston Scientific Corp·PRE 14A - Preliminary proxy statement·Q4 26·20 Oct
  • … nan, the size of the Board was increased from ten to eleven members. Mr. Brennan also has joined our Audit and Finance Committee. Mr. Brennan served as the Executive Vice President, Chief Financial Officer of <strong>Boston Scientific Corporation</strong>, a medical device and healthcare technology company, from January 2014 until his retirement in June 2025. He was the Senior Vice President, Corporate Controller from 2010 through 2013 and, prior to that role, h …
    VERTEX PHARMACEUTICALS INC / MABoston Scientific Corp·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·20 Oct

Key Stats

Trading

Px/Chg 1D$42.60 / -1.46%
Prev Close$47.80
% of 52Wk H41.08%
Avg Volume18.05M
Beta0.20
Mkt Cap63.32B
FD Mkt Cap66.86B

Float

Shrs Out/Float1.49B / 1.48B
Short Float0.02%
Days to Cover1.19
Stock Repurchased$0.00

Current Valuation

EV73.06B
EV/EBITDA12.91
EV/Sales3.54
P/B2.45
P/S3.07
FCF Yield0.27%
ROE5.17%
ROA3.01%
Current Ratio1.90

Estimates

P/E17.82
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23Apr '24Apr '25Mar '26Oct '26
PRICE-BASED RATIOS
Price / Earnings88.49107.9865.5581.65139.6847.60
Price / Sales10.445.947.339.0417.6512.23
Price / Book Value4.594.295.426.953.852.46
Price / Free Cash Flow133.0682.4761.3257.2392.11372.15
ENTERPRISE VALUE METRICS
Enterprise Value107,334.083,727.0113,302.1162,339.2103,918.373,383.5
Enterprise Value / Sales11.606.607.969.6919.6614.10
Enterprise Value / EBITDA45.8130.5532.8141.2278.6745.78
Enterprise Value / EBIT66.1052.1750.2060.82108.7058.61

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue14%11,888.012,682.014,240.016,747.020,074.0
Gross Income16.7%7,461.07,714.08,831.010,267.013,853.0
EBITDA19.3%2,518.02,741.03,453.03,938.05,102.0
EBIT27.2%1,425.01,605.02,257.02,669.03,734.0
Net Income29.1%1,040.0698.01,593.01,854.02,886.0
EPS (Diluted)29.6%0.690.451.071.251.94
BALANCE SHEET
Cash & ST Inv1.5%1,925.0928.0865.0414.02,045.0
Total Assets7.9%32,230.032,470.035,136.039,395.043,673.0
Total Liabilities5.3%15,607.014,896.015,606.017,392.019,201.0
Total Shareholder Equity9.9%16,623.017,574.019,282.021,770.024,233.0
CASH FLOW
Net Operating Cash Flow24.8%1,871.01,526.02,503.03,435.04,534.0
Cap Ex12.1%-554.0-612.0-800.0-790.0-876.0
Free Cash Flow29.1%1,316.0914.01,703.02,645.03,658.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)45.69
Basic Shares1,486.36
Market Cap67,911.8
Diluted Shares1,495.00
Fully Diluted Shares Outstanding1,495.00
Fully Diluted Market Cap68,306.6
+Consolidated Debt11,029.0
−In-the-Money Convertible Debt—
+Capital Leases124.0
+Operating Leases—
−Cash & Equivalents-1,524.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest240.0
+Pension Liabilities—
Enterprise Value77,656.8

Segment data

Revenue

by Products and services

  • Cardiovascular66%
  • Medsurg34%

Revenue

by Geography

  • United States64%
  • Non-us36%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

L3harris Technologies, Inc. /DE/

LHX US